Acute Myeloid Leukemia Refractory Clinical Trials
2 recruiting trials for Acute Myeloid Leukemia Refractory. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Acute Myeloid Leukemia Refractory clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Apollo Therapeutics Ltd (1), Oryzon Genomics S.A. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is APL-4098 (drug, 1 trial), followed by Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098.
Track Acute Myeloid Leukemia Refractory trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with...
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Acute Myeloid Leukemia Refractory, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Acute Myeloid Leukemia Refractory, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Acute Myeloid Leukemia Refractory, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.